RxDoctor Payments Data

Vincent Desantis, MD

Internal Medicine · Bristol, CTNPI 1972063741

Payments from drug & device makers

$2,380in general payments, 2019–2025

Across 78 payments — averaging $30.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$556
  • Lilly USA, LLC$377
  • AbbVie$219
  • Boehringer Ingelheim$213
  • Smith+Nephew$126
  • Pfizer$117
  • plus $771 from 12 others

What the payments were for

  • Food & beverage$2,29396%
  • Education$874%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,380 in reported general payments places this provider in the 85th percentile of 2,067 internal medicine providers in Connecticut.

See all internal medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$46,747
Medicare patients
133
Services billed
422

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide129$161,633
EliquisApixaban99$122,247
MounjaroTirzepatide56$87,107
JardianceEmpagliflozin52$77,324
FarxigaDapagliflozin Propanediol25$34,130
XareltoRivaroxaban24$31,716
CreonLipase/Protease/Amylase13$24,603
RybelsusSemaglutide12$23,261
JanuviaSitagliptin Phosphate13$22,091
Breo ElliptaFluticasone/Vilanterol26$12,295
Lantus SolostarInsulin Glargine,hum.Rec.Anlog41$6,423
Atorvastatin Calcium528$3,325
Gabapentin180$3,011
Rosuvastatin Calcium279$2,563
Fluticasone-SalmeterolFluticasone Propion/Salmeterol19$2,437

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$53$184,894141 claims
PfizerEliquis$117$122,24799 claims
Lilly USA, LLCMounjaro$377$87,10756 claims
Boehringer IngelheimJardiance$213$77,32452 claims
AstraZenecaFarxiga$556$34,13025 claims
AbbVieCreon, Synthroid$219$25,27929 claims
MerckJanuvia$21$22,09113 claims
GSKBreo Ellipta$99$12,29526 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,067 internal medicine providers in Connecticut.

Other internal medicine in Bristol

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →